NVS Jan 2025 100.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

3.3000

-3.4200

(-50.89%)

As of 10:12AM EST. Market open.

Simply Wall St.
Novartis (VTX:NOVN) Is Paying Out A Larger Dividend Than Last Year
Novartis AG's ( VTX:NOVN ) dividend will be increasing from last year's payment of the same period to $3.20 on 13th of...
GlobeNewswire
Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®
In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to improve beyond the primary endpoint analysis at Week 16 to more than 55% at Week 52, as evaluated by the HS Clinical Response (HiSCR) measure1 Safety findings were consistent with the well-established safety profile of Cosentyx in its approved indications1 HS is a recurrent skin disease affecting one in 100 people worldwide, causing painful, boil-like a
Simply Wall St.
Novartis Full Year 2022 Earnings: Misses Expectations
Novartis ( VTX:NOVN ) Full Year 2022 Results Key Financial Results Revenue: US$51.8b (down 2.0% from FY 2021). Net...